Azure Health Technology Limited



ABN: 35 111 082 485

Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000

www.azureht.com.au | Tel: +61 2 8279 8908

VGI Health Technology (NSX:VTL) receives finished nutraceutical products in the US

Sydney New South Wales, **15 June 2021** – Further to our announcement on 16 March 2021 that the first manufacturing run for our finished nutraceutical products has been completed, Azure Health Technology Limited trading as VGI Health Technology (the **Company** or **VTL**) is pleased to announce that we have now received these products in our warehouse in Florida, USA and they are ready for sale in the US.

VTL's CEO and Managing Director, Dr Glenn Tong, said that this is a major milestone for VTL as we are now commencing the launch of both our patented nutraceutical products, NE1-Elite® for reduction of Delayed Onsent Muscle Soreness (DOMS) and NE1-Heart® for maintenance of heart health in the US.

For more information please contact:

Glenn Tong, CEO and Managing Director Ph: +61 (0) 412 193 350

Andrew Crook, Investor and Media Relations Ph:+61 (0) 419 788 431

Catriona Glover, Company Secretary Tel: +61 (0) 402 328 200

About Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL)

Azure Health Technology Limited trading as VGI Health Technology is an Australian public biotechnology company listed on the National Stock Exchange (NSX) with the ticker code NSX:VTL. VTL is developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: https://www.azureht.com.au. To track VTL on the NSX, see: https://www.nsx.com.au/summary/VTL. Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp